Delcath Systems, Inc. (DCTH)
NASDAQ: DCTH · IEX Real-Time Price · USD
-0.14 (-1.72%)
At close: Jul 11, 2024, 4:00 PM
+0.01 (0.12%)
After-hours: Jul 11, 2024, 5:36 PM EDT

Company Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.

It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.

Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Delcath Systems, Inc.
Delcath Systems logo
Country United States
Founded 1988
Industry Medical Devices
Sector Healthcare
Employees 76
CEO Gerard J. Michel MBA, MS

Contact Details

566 Queensbury Avenue
Queensbury, New York 12804
United States
Phone (518) 743-8892

Stock Details

Ticker Symbol DCTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000872912
CUSIP Number 24661P807
ISIN Number US24661P8077
Employer ID 06-1245881
SIC Code 3841

Key Executives

Name Position
Gerard J. Michel MBA, MS Chief Executive Officer and Director
Dr. Johnny John M.D. Senior Vice President of Clinical Operations and Medical Affairs
Sandra Pennell Senior Vice President of Finance and Principal Financial and Accounting Officer
Dr. Martha S. Rook Ph.D. Chief Operating Officer
David Hoffman General Counsel, Corporate Secretary and Chief Compliance Officer
Dr. Vojislav Vukovic M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Jul 9, 2024 144 Filing
Jul 9, 2024 8-K Current Report
Jun 28, 2024 S-3 Registration statement under Securities Act of 1933
Jun 28, 2024 S-8 Securities to be offered to employees in employee benefit plans
May 29, 2024 8-K Current Report
May 17, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
May 9, 2024 EFFECT Notice of Effectiveness
May 9, 2024 424B3 Prospectus